-
51.发明授权Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases 失效细胞粘附分子表达的反义调控和细胞粘附分子相关疾病的治疗
公开(公告)号：US6096722A
公开(公告)日：2000-08-01
申请号：US85759
申请日：1998-05-27
IPC分类号： A01N43/04 , A61K31/70 , A61K38/00 , A61K48/00 , C07H21/00 , C07H21/02 , C07H21/04 , C12N15/113 , C12P19/34 , C12Q1/68
CPC分类号： C12N15/1138 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346
摘要： Compositions and methods are provided for the modulation of expression of cellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. Methods of modulating expression of cellular adhesion molecules are provided, as are methods of treating conditions associated with cellular adhesion molecules. In a preferred embodiment, the cellular adhesion molecule is ICAM-1, and a preferred antisense sequence targeted to human ICAM-1 is demonstrated to have clinical utility in several disease indications.
摘要翻译： 提供组合物和方法用于调节细胞粘附分子的表达。 根据优选实施方案，提供了与编码细胞间粘附分子-1，血管细胞粘附分子-1和内皮细胞粘附分子-1的核酸特异性杂交的寡核苷酸。 提供调节细胞粘附分子表达的方法，以及治疗与细胞粘附分子相关的病症的方法。 在优选的实施方案中，细胞粘附分子是ICAM-1，并且针对人ICAM-1的优选反义序列证明在几种疾病适应症中具有临床效用。
-
公开(公告)号：US6015894A
公开(公告)日：2000-01-18
申请号：US982845
申请日：1997-12-02
IPC分类号： A01N43/04 , A61K31/70 , A61K48/00 , C07H21/00 , C07H21/02 , C07H21/04 , C12N15/00 , C12P19/34 , C12Q1/68
CPC分类号： C07H21/04 , A61K48/00 , C07K14/70525 , C07K14/70542 , C07K14/70564 , C12N15/1138 , A61K38/00 , C12N2310/315 , C12N2310/322 , C12N2310/352 , C12N2310/3533
摘要： Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of the synthesis or metabolism of intercellular adhesion molecules. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and endothelial leukocyte adhesion molecule-1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a transcription initiation site, a translation initiation site, 5'-untranslated sequences, 3'-untranslated sequences, and intervening sequences. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating cell adhesion proteins with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to one of the foregoing proteins are disclosed. Methods for treatment of diseases responding to modulation cell adhesion molecules are disclosed.
摘要翻译： 提供组合物和方法，用于治疗和诊断适于通过调节细胞间粘附分子的合成或代谢来治疗的疾病。 根据优选实施方案，提供了与编码细胞间粘附分子-1，血管细胞粘附分子-1和内皮细胞粘附分子-1的核酸特异性杂交的寡核苷酸。 所述寡核苷酸包含足以实现所述特异性杂交的同一性和数目的核苷酸单元。 在其它优选实施方案中，寡核苷酸与转录起始位点，翻译起始位点，5'-非翻译序列，3'非翻译序列和插入序列特异性杂交。 公开了通过用与上述蛋白质之一相对应的RNA或DNA特异性杂交的寡核苷酸调节细胞粘附蛋白来治疗患有治疗性干预的疾病的方法。 公开了治疗响应于调节细胞粘附分子的疾病的方法。
-
公开(公告)号：US6008344A
公开(公告)日：1999-12-28
申请号：US255893
申请日：1999-02-23
申请人： C. Frank Bennett , Lex M. Cowsert
发明人： C. Frank Bennett , Lex M. Cowsert
CPC分类号： C12N15/1137 , C12Y301/01004 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , Y02P20/582
摘要： Antisense compounds, compositions and methods are provided for modulating the expression of Phospholipase A2 Group IV. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Phospholipase A2 Group IV. Methods of using these compounds for modulation of Phospholipase A2 Group IV expression and for treatment of diseases associated with expression of Phospholipase A2 Group IV are provided.
摘要翻译： 提供反义化合物，组合物和方法用于调节磷脂酶A2组IV的表达。 组合物包含靶向编码磷脂酶A2组IV的核酸的反义化合物，特别是反义寡核苷酸。 提供了使用这些化合物调节磷脂酶A2组IV表达和治疗与磷脂酶A2组IV表达相关疾病的方法。
-
公开(公告)号：US5958771A
公开(公告)日：1999-09-28
申请号：US205144
申请日：1998-12-03
IPC分类号： C12N15/09 , A61K31/7115 , A61K31/712 , A61K31/7125 , A61K31/713 , A61K38/00 , A61K48/00 , A61P35/00 , A61P37/00 , C12N15/113 , C07H21/04 , C12N15/85 , C12Q1/68
CPC分类号： C12N15/113 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , Y02P20/582
摘要： Antisense compounds, compositions and methods are provided for modulating the expression of Cellular Inhibitor of Apoptosis-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Cellular Inhibitor of Apoptosis-2. Methods of using these compounds for modulation of Cellular Inhibitor of Apoptosis-2 expression and for treatment of diseases associated with expression of Cellular Inhibitor of Apoptosis-2 are provided.
-
公开(公告)号：US5955443A
公开(公告)日：1999-09-21
申请号：US44506
申请日：1998-03-19
IPC分类号： C12N15/09 , A61K31/711 , A61K38/00 , A61K48/00 , A61P1/04 , A61P9/00 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/00 , A61P37/06 , A61P43/00 , C12N15/113 , C12P19/34 , C12Q1/68 , C07H21/04
CPC分类号： C12N15/1138 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346
摘要： Compositions and methods for the treatment and diagnosis of diseases or disorders amenable to treatment through modulation of expression of a nucleic acid encoding a platelet endothelial cell adhesion molecule-1 (PECAM-1; also known as CD31 antigen or endoCAM) protein are provided.
摘要翻译： 提供了用于治疗和诊断易于通过调节编码血小板内皮细胞粘附分子-1（PECAM-1;也称为CD31抗原或endoCAM）蛋白的核酸的表达进行治疗的疾病或病症的组合物和方法。
-
公开(公告)号：US5885970A
公开(公告)日：1999-03-23
申请号：US488177
申请日：1995-06-07
申请人： C. Frank Bennett , Nicholas Dean
发明人： C. Frank Bennett , Nicholas Dean
IPC分类号： A61K38/00 , A61K48/00 , C07H21/00 , C07K14/705 , C12N9/12 , C12N15/113 , C12Q1/68 , C07H21/04 , C12N15/85
CPC分类号： A61K48/00 , C07H21/00 , C07K14/70564 , C12N15/1137 , C12N9/12 , C12Q1/6876 , C12Q1/6883 , C12Y207/11013 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/3521 , C12N2310/3527 , C12N2310/3533 , C12Q2600/158
摘要： Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. Oligonucleotides specifically hybridizable with a translation initiation site, 5'-untranslated region or 3'-untranslated region are provided. Oligonucleotides specifically hybridizable with a particular PKC isozyme or set of isozymes are also provided. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide targeted to PKC are disclosed.
-
57.发明授权Antisense compositions and methods for modulating type I interleukin-1 receptor expression 失效用于调节I型白细胞介素-1受体表达的反义组合物和方法
公开(公告)号：US5856099A
公开(公告)日：1999-01-05
申请号：US651692
申请日：1996-05-21
申请人： Loren Miraglia , C. Frank Bennett , Nicholas Dean , Thomas Geiger
发明人： Loren Miraglia , C. Frank Bennett , Nicholas Dean , Thomas Geiger
CPC分类号： C12N15/1138 , C07H21/00 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/322
摘要： Compositions and methods are provided for the treatment and diagnosis of diseases amenable to treatment through modulation of type I IL-1 receptor mRNA expression. In accordance with preferred embodiments, oligomers are provided which are specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor. Methods of modulating type I IL-1 receptor expression and of treating animals suffering from diseases amenable to therapeutic intervention by modulating the expression of type I interleukin-1 receptor with an oligomer specifically hybridizable with DNA or RNA encoding type I interleukin-1 receptor are disclosed.
摘要翻译： 提供组合物和方法用于治疗和诊断易于通过调节I型IL-1受体mRNA表达的治疗。 根据优选的实施方案，提供可与编码I型白细胞介素-1受体的DNA或RNA特异性杂交的寡聚体。 公开了调节I型IL-1受体表达的方法和通过用与编码I型白细胞介素-1受体的DNA或RNA特异性杂交的寡聚体调节I型白细胞介素-1受体的表达来治疗患有适于治疗性干预的疾病的动物的方法 。
-
公开(公告)号：US5703054A
公开(公告)日：1997-12-30
申请号：US89996
申请日：1993-07-09
申请人： C. Frank Bennett , Nicholas Dean
发明人： C. Frank Bennett , Nicholas Dean
IPC分类号： C12N15/09 , A61K31/70 , A61K31/7088 , A61K38/00 , A61K48/00 , A61P29/00 , A61P35/00 , C07H21/00 , C07H21/04 , C12N9/12 , C12N15/113 , C12Q1/68
CPC分类号： C12N15/1137 , A61K48/00 , C07H21/00 , C12N9/12 , C12Q1/6876 , C12Q1/6883 , C12Y207/11013 , A61K38/00 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/341 , C12N2310/346 , C12N2310/3521 , C12N2310/3527 , C12N2310/3533 , C12Q2600/158
摘要： Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are specifically hybridizable with nucleic acid encoding PKC. Oligonucleotides specifically hybridizable with a translation initiation site, 5'-untranslated region or 3'-untranslated region are provided. Oligonucleotides specifically hybridizable with a particular PKC isozyme or set of isozymes are also provided. Methods of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression with an oligonucleotide specifically hybridizable with RNA or DNA corresponding to PKC are disclosed.
摘要翻译： 提供组合物和方法用于治疗和诊断与蛋白激酶C相关的疾病。提供与编码PKC的核酸特异性杂交的寡核苷酸。 提供了与翻译起始位点，5'-非翻译区或3'非翻译区特异性杂交的寡核苷酸。 还提供了与特定PKC同功酶或同功酶组特异性杂交的寡核苷酸。 公开了通过用与PKC相对应的RNA或DNA特异性杂交的寡核苷酸调节蛋白激酶C表达来治疗患有治疗性干预的疾病的方法。
-
公开(公告)号：US09006198B2
公开(公告)日：2015-04-14
申请号：US13577622
申请日：2011-02-08
申请人： C. Frank Bennett , Michael Hayden , Susan M. Freier , Sarah Greenlee , Jeffrey Carroll , Simon Warby , Eric E. Swayze
发明人： C. Frank Bennett , Michael Hayden , Susan M. Freier , Sarah Greenlee , Jeffrey Carroll , Simon Warby , Eric E. Swayze
IPC分类号： C12N15/11 , C12Q1/68 , C12N15/113
CPC分类号： C12Q1/6883 , C12N15/113 , C12N2310/11 , C12N2320/34 , C12Q1/6811 , C12Q1/6897 , C12Q2600/136 , C12Q2600/156 , C12Q2600/158 , C12Q2525/207 , C12Q2535/131 , C12Q2539/107 , C12Q2521/327 , C12Q2525/121 , C12Q2525/185
摘要： Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a huntingtin gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate Huntington's Disease (HD).
摘要翻译： 本文公开了用于选择性降低含有单核苷酸多态性（SNP）的亨廷顿氏基因的等位变体的表达的反义化合物和方法。 这些方法，化合物和组合物可用于治疗，预防或改善亨廷顿病（HD）。
-
公开(公告)号：US08957040B2
公开(公告)日：2015-02-17
申请号：US13577616
申请日：2011-02-08
IPC分类号： C12N15/11 , C12Q1/68 , C12N15/113
CPC分类号： C12N15/113 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2320/34
摘要： Disclosed herein are antisense compounds and methods for selectively of reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative, such as Huntington's Disease (HD).
摘要翻译： 本文公开了用于选择性降低含有单核苷酸多态性（SNP）的基因的等位变体的表达的反义化合物和方法。 这些方法，化合物和组合物可用于治疗，预防或改善疾病，包括神经变性如亨廷顿病（HD）。
-
-
-
-
-
-
-
-
-
搜索结果
198 条记录 (耗时 0.036 秒)
